Drug Profile
ZL 1101
Alternative Names: ZL-1101Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator UCB
- Developer ZAI Lab
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Graft-versus-host disease; Inflammatory bowel diseases
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Graft-versus-host disease in China (Parenteral) (Zai Lab pipeline, September 2023)
- 04 Sep 2023 Discontinued - Preclinical for Inflammatory bowel diseases in China (Parenteral) (Zai Lab pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Graft-versus-host-disease in China (Parenteral)